Many promising microphysiological systems (MPS) fail to progress beyond the laboratory because end users need confidence that they can reliably predict human responses and fit within existing drug development workflows. To achieve that, we need robust, scalable approaches for manufacturing and operating MPS that can be readily integrated into existing drug development workflows.

MiPSET's Manufacturing & Scale-Up Program addresses these challenges by developing manufacturing-compatible MPS technologies and scalable production processes from the outset. Through advances in additive manufacturing, automation, biomaterials and tissue engineering, the program is creating the tools and workflows needed to transform research prototypes into robust, reproducible technologies that can be produced, deployed and adopted by end-users.